Which of the following statements is true about the management of early-stage aspergillosis?

• A. Start antifungal therapy based on radiographic suspicion; confirm with biomarkers.
• B. Wait for cultures to turn positive.
• C. Use only antibacterial therapy.
• D. Avoid antifungal therapy altogether.

Answer: (A)

In early suspected aspergillosis, the best approach is to start antifungal therapy based on imaging and clinical context, then use biomarkers to confirm the diagnosis. This matters because radiographic signs—such as nodules with a halo or other lesions on CT—can strongly suggest invasive aspergillosis in high-risk patients, and waiting for cultures can delay life-saving treatment. Cultures often take time to become positive and can be negative even when infection is present, so starting treatment promptly while you gather confirmatory evidence is crucial.

Biomarkers like galactomannan in serum or bronchoalveolar lavage, and, to some extent, beta-D-glucan, help support the diagnosis and guide decisions about duration and intensity of therapy without delaying treatment. Using antifungal therapy alone would be inappropriate here, since this is a fungal infection, not bacterial, and delaying treatment until cultures turn positive can worsen outcomes. Avoiding antifungals altogether would be dangerous in patients with suspected invasive disease.

So the emphasis is on acting quickly when imaging and clinical risk point toward aspergillosis, with biomarkers used to confirm and refine management rather than waiting for culture confirmation.